Stocks of Plus Therapeutics Inc (NASDAQ:PSTV) traded higher last session on Wall Street, up 10.38% to $0.35.
PSTV stock price is now -24.38% away from the 50-day moving average and -65.78% away from the 200-day moving average. The market capitalization of the company currently stands at $17.74M.
With the price target of $9, D. Boral Capital recently initiated with Buy rating for Plus Therapeutics Inc (NASDAQ: PSTV). On January 25, 2021, Ladenburg Thalmann recently initiated its ‘Buy’ rating on the stock quoting a target price of $8, while ‘Maxim Group’ rates the stock as ‘Buy’
In other news, Petersen Greg, Director bought 36,666 shares of the company’s stock on May 15 ’25. The stock was bought for $20,276 at an average price of $0.55. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 13 ’24, Director Hawkins Richard J bought 4,000 shares of the business’s stock. A total of $5,996 was incurred on buying the stock at an average price of $1.50. This leaves the insider owning 15,188 shares of the company worth $5315.8. A total of 0.62% of the company’s stock is owned by insiders.
During the past 12 months, Plus Therapeutics Inc has had a low of $0.16 and a high of $2.31. The fifty day moving average price for PSTV is $0.4604 and a two-hundred day moving average price translates $1.0165 for the stock.
The latest earnings results from Plus Therapeutics Inc (NASDAQ: PSTV) was released for 2025-03-31. The company reported revenue of $1.06 million for the quarter, compared to $1.68 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -36.85 percent.
